MedPath

Survey research on the effects of statin alone or a combination of statin and EPA on endothelial function in patients with type 2 diabetes complicated with dyslipidemia

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000005783
Lead Sponsor
The Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University
Brief Summary

In patients with type 2 diabetes and receiving statin therapy whose LDL-C level was less than 100 mg/dL, the addition of highly purified EPA for 6 months significantly improved vascular function.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Those patients who meet any of the following conditions were excluded from the current study: 1) Currently suffer from cerebral hemorrhage or have had it in the past 2) Have embolism or hemorrhagic infarction 3) Are currently suffering from a hemorrhage (conditions such as hemophilia, capillary fragility, hemorrhage from the digestive system, urinary tract hemorrhage, hemoptysis, and vitreous hemorrhage) 4) Have severe congestive heart failure 5) Have a history of hypersensitivity to statin or components of EPA 6) Have a peptic ulcer 7) Have a severe hematological anomaly 8) Have a severe complication (such as a malignant tumor, liver cirrhosis, renal failure and heart failure) 9) Those who failed to give informed consent 10) Other patients whom the chief investigator or attending physician finds unsuitable

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath